Cefdinir: An oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 1, 2007, Pages 29-43

  Sader, Helio S ^a,b   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute otitis media; Cefdinir; Group A streptococcal pharyngitis; Haemophilus influenzae; Oral cephalosporin; Palatability; Respiratory tract infections; Skin and skin structure infections; Streptococcus pneumoniae; Toleration; uSSTI

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CAPTOPRIL; CEFACLOR; CEFALEXIN; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CEFUROXIME AXETIL; COTRIMOXAZOLE; ERYTHROMYCIN; FERROUS SULFATE; LEVOFLOXACIN; LORACARBEF; MACROLIDE; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; PROBENECID; QUINAPRIL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; VITAMIN; CEPHALOSPORIN DERIVATIVE;

ACUTE OTITIS MEDIA; ACUTE SINUSITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BICARBONATE BLOOD LEVEL; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISABILITY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FLATULENCE; FOOD; FOOD DRUG INTERACTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAEMOPHILUS INFLUENZAE; HEMATURIA; HUMAN; LEUKOCYTURIA; LOOSE FECES; LOW DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PALATABILITY; PATIENT COMPLIANCE; PHARYNGITIS; PROTEIN URINE LEVEL; PSEUDOMEMBRANOUS COLITIS; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SUSPENSION; SYSTEMATIC REVIEW; TONSILLITIS; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CEPHALOSPORINS; HUMANS; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, INFECTIOUS;

EID: 33947726168     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.1.29     Document Type: Article

References (65)

1. Brotzu G. Ricerche su di un nuovo antibiotico. Lavori dell'Instituto, D'Igiene di Cagliari (1948).
2. Wick WE. Cephalexin, a new orally absorbed cephalosporin antibiotic. Appl. Microbiol. 15(4), 765-769 (1967).
3. Klein JO, McCracken GH Jr. Summary: role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children. Pediatr. Infect. Dis. J. 19(12 Suppl.), S181-S183 (2000).
4. Bryskier A, LeBel M. Oral cephalosporins. In: Antimicrobial Agents: Antibacterials and Antifungals. Bryskier A (Ed.) ASM Press, Washington, DC, USA 222-268 (2005).
5. Low DE. The new oral cephalosporins in community-acquired infections. Clin. Microbiol. Infect. 6(Suppl. 3), 64-69 (2000).
6. Guay DR. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. Pediatr. Infect. Dis. J. 19(12 Suppl.), S141-S146 (2000).
7. Guay DR. Cefdinir: an expanded-spectrum oral cephalosporin. Ann. Pharmacother. 34(12), 1469-1477 (2000).
8. Neu HC, Chin NX, Labthavikul P. Comparative in vitro activity and β-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob. Agents Chemother. 26(2), 174-180 (1984).
9. Buschelman BJ, Jones RN, Bale MJ. Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci. J. Clin. Microbiol. 32(2), 565-567 (1994).
10. Briggs BM, Jones RN, Erwin ME, Barrett MS, Johnson DM. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Diagn. Microbiol. Infect. Dis. 14(5), 425-434 (1991).
11. Cohen MA, Joannides ET, Roland GE et al. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and β-lactamase stability. Diagn. Microbiol. Infect. Dis. 18(1), 31-39 (1994).
12. Doern GV. Activity of oral β-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance. Otolaryngol. Head Neck Surg. 127(6 Suppl.), S17-S23 (2002).
13. Gerlach EH, Jones RN, Allen SD et al. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines. Diagn. Microbiol. Infect. Dis. 15(6), 537-543 (1992).
14. Inamoto Y, Chiba T, Kamimura T, Takaya T. FK 482, a new orally active cephalosporin synthesis and biological properties. J. Antibiot. (Tokyo) 41(6), 828-830 (1988).
15. Mine Y, Kamimura T, Watanabe Y et al. In vitro antibacterial activity of FK482, a new orally active cephalosporin. J. Antibiot. Tokyo) 41(12), 1873-1887 (1988).
16. Neu HC, Saha G, Chin NX. Comparative in vitro activity and β-lactamase stability of FK482, a new oral cephalosporin. Antimicrob. Agents Chemother. 33(10), 1795-1800 (1989).
17. Scriver SR, Willey BM, Low DE, Simor AE. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 11(7), 646-652 (1992).
18. Wise R, Andrews JM, Thornber D. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin. J. Antimicrob. Chemother. 28(2), 239-248 (1991).
19. Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagn. Microbiol. Infect. Dis. 47(3), 515-525 (2003).
20. CLSI. Clinical and Laboratory Standards Institute. M7-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. CLSI, PA, USA (2006)
21. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41 (10), 1373-1406 (2005).
22. Tack KJ, Keyserling CH, McCarty J, Hedrick JA. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group. Antimicrob. Agents Chemother. 41(4), 739-742 (1997).
23. Tack KJ, Littlejohn TW, Mailloux G, Wolf MM, Keyserling CH. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clin. Ther. 20(2), 244-256 (1998).
24. Sader HS, Streit JM, Fritsche TR, Jones RN. Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates. Diagn. Microbiol. Infect. Dis. 49(4), 283-287 (2004).
25. Jones RN, Sader HS. Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections (uSSTI) in North America: are we evaluating the orally administered cephalosporins correctly? Diagn. Microbiol. Infect. Dis. 55(4), 351-356 (2006).
26. CLSI. Clinical and Laboratory Standards Institute. M100-S16, Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI, PA, USA (2006)
27. Omnicef® (cefdinir) package insert. Abbott Laboratories, IL, USA (2006).
28. Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs 64(13), 1433-1464 (2004).
29. Guay DR. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. Clin. Ther. 24(4), 473-489 (2002).
30. Cook PJ, Andrews JM, Wise R, Honeybourne D. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments. J. Antimicrob. Chemother. 37(2), 331-339 (1996).
31. Richer M, Allard S, Manseau L, Vallee F, Pak R, LeBel M. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses. Antimicrob. Agents Chemother. 39(5), 1082-1086 (1995).
32. Bowlware KL, McCracken GH Jr, Lozano-Hernandez J, Ghaffar F. Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily. Pediatr. Infect. Dis. J. 25(3), 208-210 (2006).
33. Hishida A, Ohishi K, Nagashima S, Kanamaru M, Obara M, Kitada A. Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. Antimicrob. Agents Chemother. 42(7), 1718-1721 (1998).
34. Tomino Y, Fukui M, Hamada C, Inoue S, Osada S. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis. Arzneimittelforschung 48(8), 862-867 (1998).
35. Ueno K, Tanaka K, Tsujimura K et al. Impairment of cefdinir absorption by iron ion. Clin. Pharmacol. Ther. 54(5), 473-475 (1993).
36. Jacolot A, Tod M, Petitjean O. Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats. Antimicrob. Agents Chemother. 40(4), 979-982 (1996).
37. Paster RZ, McAdoo MA, Keyserling CH, Nemeth MA, Tack KJ, Griffin TJ. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis. Int. J. Clin. Pract. 54(5), 293-299 (2000).
38. Fogarty CM, Bettis RB, Griffin TJ, Keyserling CH, Nemeth MA. Tack KJ. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 45(6), 851-858 (2000).
39. Van Herwaarden CL, Langan CE, Siemon G et al. International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis. Int. J. Infect. Dis. 4(1), 26-33 (2000).
40. Drehobl M, Bianchi P, Keyserling CH, Tack KJ, Griffin TJ. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. Antimicrob. Agents Chemother. 41(7), 1579-1583 (1997).
41. Gwaltney JM Jr, Savolainen S, Rivas P et al. Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group. Antimicrob. Agents Chemother. 41(7), 1517-1520 (1997).
42. Steurer M, Schenk P. Efficacy and safety of cefdinir in the treatment of maxillary sinusitis. Eur. Arch. Otorhinolaryngol. 257(3), 140-148 (2000).
43. Henry DC, Kapral D, Busman TA, Paris MM. Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study. Clin. Ther. 26(12), 2026-2033 (2004).
44. Nemeth MA, McCarty J, Gooch WM III, Henry D, Keyserling CH, Tack KJ. Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group. Clin. Ther. 21(11), 1873-1881 (1999).
45. Nemeth MA, Gooch WM III, Hedrick J, Slosberg E, Keyserling CH, Tack KJ. Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis. Clin. Ther. 21(9), 1525-1532 (1999).
46. Pichichero M, Casey J. Comparison of European and U.S. results for cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis. Eur. J. Clin. Microbiol. Infect. Dis. 25(6), 354-364 (2006).
47. Casey JR, Pichichero ME. Meta-analysis of short course antibiotic treatment for group A streptococcal tonsillopharyngitis. Pediatr. Infect. Dis. J. 24(10), 909-917 (2005).
48. Brook I, Foote PA. Efficacy of penicillin versus cefdinir in eradication of group A streprococci and tonsillar flora. Antimicrob. Agents Chemother. 49(11), 4787-4788 (2005).
49. Pichichero, ME. Evidence for copathogenicity as a mechanism for bacterial resistance. Infect. Dis. Clin. Prac. 4(Suppl.), S248-S253 (1998).
50. Tack KJ, Keyserling CH, McCarty J, Hedrick JA. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group. Antimicrob. Agents Chemother. 41(4), 739-742 (1997).
51. Giordano PA. Elston D, Akinlade BK et al. Cefdinir versus cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults. Curr. Med. Res. Opin. 22(12), 2419-2428 (2006).
52. Lee MC, Rios AM, Aten MF et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 23(2), 123-127 (2004).
53. Young DM, Harris HW, Charlebois ED et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch. Surg. 139(9), 947-951; discussion 951-943 (2004).
54. Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352(14), 1436-1444 (2005).
55. Chambers HF. Community-associated MRSA - resistance and virulence converge. N. Engl. J. Med. 352(14), 1485-1487 (2005).
56. Adler M, McDonald PJ, Trostmann U, Keyserling C, Tack K. Cefdinir vs. amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children. Pediatr. Infect. Dis. J. 19(12 Suppl.), S166-S170 (2000).
57. Block SL, McCarty JM, Hedrick JA, Nemeth MA, Keyserling CH, Tack KJ. Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children. Pediatr. Infect. Dis. J. 19(12 Suppl.), S159-S165 (2000).
58. Block SL, Kratzer J, Nemeth MA, Tack KJ. Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media. Pediatr. Infect. Dis. J. 19(12 Suppl.), S147-S152 (2000).
59. Arguedas A, Dagan R, Leibovitz E, Hoberman A, Pichichero M, Paris M. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr. Infect. Dis. J. 25(3), 211-218 (2006).
60. Block SL, Busman TA, Paris MM, Bukofzer S. Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media. Pediatr. Infect. Dis. J. 23(9), 836-838 (2004).
61. Block SL, Schmier JK, Notario GF et al. Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/ clavulanate oral suspension for acute otitis media in young children. Curr. Med. Res. Opin. 22(9), 1839-1847 (2006).
62. Holas C, Chiu YL, Notario G, Kapral D. A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years. Clin. Ther. 27(12), 1950-1960 (2005).
63. Steele RW, Thomas MP, Begue RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr. Infect. Dis. J. 20(1), 1-5 (2001).
64. Powers JL, Gooch WM III, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr. Infect. Dis. J. 19(12 Suppl.), S174-S180 (2000).
65. Felmingham D. Review of the comparative in vitro activity of some oral cephalosporins. Infect. Dis. Clin. Prac. 7(Suppl. 2), 75-80 (1998).